Hydrochloric Acid → (S)-2-(methyl(4-(5-(morpholin-2-ylmethylamino)pyrido[4,3-b]pyrazin-7-yl)phenyl)amino)ethanol
反応式
[OH:1][CH2:2][CH2:3][N:4]([CH3:36])[C:5]1[CH:10]=[CH:9][C:8]([C:11]2[N:20]=[C:19]([NH:21][CH2:22][C@H:23]3[O:28][CH2:27][CH2:26][N:25](C(OC(C)(C)C)=O)[CH2:24]3)[C:18]3[C:13](=[N:14][CH:15]=[CH:16][N:17]=3)[CH:12]=2)=[CH:7][CH:6]=1.Cl>CC(=O)OCC>[CH3:36][N:4]([C:5]1[CH:6]=[CH:7][C:8]([C:11]2[N:20]=[C:19]([NH:21][CH2:22][C@H:23]3[O:28][CH2:27][CH2:26][NH:25][CH2:24]3)[C:18]3[C:13](=[N:14][CH:15]=[CH:16][N:17]=3)[CH:12]=2)=[CH:9][CH:10]=1)[CH2:3][CH2:2][OH:1]参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
(R)-tert-butyl 2-((7-(4-((2-hydroxyethyl)(methyl)amino)phenyl)pyrido[4,3-b]pyrazin-5-ylamino)methyl)morpholine-4-carboxylate was dissolved in EA (20 mL), 5M HCl in EA (10 mL) was added, the mixture was stirred at room temperature overnight. It was concentrated, treated with NH3.H2O, concentrated, purified by preparative TLC to give 10 mg reddish-brown solid. MS (m/z): 395 (M+H)+